BACKGROUND: Synovial sarcoma is the third most common pediatric soft tissue tumor. It requires an aggressive approach to achieve a cure. However, optimal treatment modalities adapted to disease extension and histologic variants have not been determined because there is little information about prospectively treated patients. METHODS: A multicenter trial for soft tissue sarcomas (Protocol CWS 81) was conducted in West Germany between 1981-1985, and 31 patients with synovial sarcoma were registered. Treatment included multiagent chemotherapy and irradiation after initial tumor excision or biopsy. The male-female ratio in this group was 1:1.6 with a median age of 14 years (range, 1-19 years). The median follow-up time after diagnosis was 101 months (range, 77-131 months). RESULTS: The overall event-free survival (EFS) for patients with synovial sarcoma was 74.2% at 5 years. Group I-II tumors had a significantly better prognosis than those in Group III-IV (EFS at 5 years 84.4% and 58.3%, respectively; P = 0.024). Small tumors (< 5 cm) responded better than larger tumors (> or = 5 cm; EFS, 93% versus 58%; P = 0.029). Synovial sarcoma involved the extremities in 28 patients who had a better outcome compared with those with extremity rhabdomyosarcoma in this study (EFS for Group I-IV was 82% versus 24%, P = 0.001). CONCLUSIONS: The results appeared superior to previous experience using radical surgery alone and suggested that after initial, nonmutilating surgery, adjuvant chemotherapy, and irradiation contributed to the improved long-term survival.
BACKGROUND:Synovial sarcoma is the third most common pediatric soft tissue tumor. It requires an aggressive approach to achieve a cure. However, optimal treatment modalities adapted to disease extension and histologic variants have not been determined because there is little information about prospectively treated patients. METHODS: A multicenter trial for soft tissue sarcomas (Protocol CWS 81) was conducted in West Germany between 1981-1985, and 31 patients with synovial sarcoma were registered. Treatment included multiagent chemotherapy and irradiation after initial tumor excision or biopsy. The male-female ratio in this group was 1:1.6 with a median age of 14 years (range, 1-19 years). The median follow-up time after diagnosis was 101 months (range, 77-131 months). RESULTS: The overall event-free survival (EFS) for patients with synovial sarcoma was 74.2% at 5 years. Group I-II tumors had a significantly better prognosis than those in Group III-IV (EFS at 5 years 84.4% and 58.3%, respectively; P = 0.024). Small tumors (< 5 cm) responded better than larger tumors (> or = 5 cm; EFS, 93% versus 58%; P = 0.029). Synovial sarcoma involved the extremities in 28 patients who had a better outcome compared with those with extremity rhabdomyosarcoma in this study (EFS for Group I-IV was 82% versus 24%, P = 0.001). CONCLUSIONS: The results appeared superior to previous experience using radical surgery alone and suggested that after initial, nonmutilating surgery, adjuvant chemotherapy, and irradiation contributed to the improved long-term survival.
Authors: Bernhard M Speth; Andreas H Krieg; Andre Kaelin; G Ulrich Exner; Louis Guillou; Arthur von Hochstetter; Gernot Jundt; Fritz Hefti Journal: J Child Orthop Date: 2011-08-11 Impact factor: 1.548
Authors: Rajkumar Venkatramani; Wei Xue; R Lor Randall; Suzanne Wolden; James Anderson; Dolores Lopez-Terrada; Jennifer Black; Simon C Kao; Barry Shulkin; Andrew Ostrenga; Alberto Pappo; Sheri L Spunt Journal: J Clin Oncol Date: 2021-10-08 Impact factor: 44.544
Authors: Fritz C Eilber; Murray F Brennan; Frederick R Eilber; Jeffery J Eckardt; Stephen R Grobmyer; Elyn Riedel; Charles Forscher; Robert G Maki; Samuel Singer Journal: Ann Surg Date: 2007-07 Impact factor: 12.969
Authors: C Chakiba; P Lagarde; D Pissaloux; A Neuville; C Brulard; G Pérot; J M Coindre; P Terrier; D Ranchere-Vince; A Ferrari; P Collini; A J H Suurmeijer; J Y Blay; S A Terrisse; S Piperno-Neumann; G Averous; B Bui; D Orbach; A Italiano; F Chibon Journal: Ann Oncol Date: 2014-07-28 Impact factor: 32.976
Authors: H Al-Hussaini; D Hogg; M E Blackstein; B O'Sullivan; C N Catton; P W Chung; A M Griffin; D Hodgson; S Hopyan; R Kandel; P C Ferguson; J S Wunder; A A Gupta Journal: Sarcoma Date: 2011-04-14
Authors: Yasir Khan; Richard Carey-Smith; Mandy Taylor; Jennifer Woodhouse; Angela Jacques; David Wood; Anne Long Journal: Cancer Rep (Hoboken) Date: 2020-09-03
Authors: Monika Scheer; Christian Vokuhl; Sebastian Bauer; Jörg Fuchs; Steffan Loff; Beate Timmermann; Marc Münter; Anton George Henssen; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Ewa Koscielniak; Thomas Klingebiel Journal: J Cancer Res Clin Oncol Date: 2021-07-17 Impact factor: 4.553